TY - JOUR
T1 - Animal inflammation-based models of depression and their application to drug discovery
AU - Ma, Li
AU - Demin, Konstantin A.
AU - Kolesnikova, Tatyana O.
AU - Kharsko, Sergey L.
AU - Zhu, Xiaokang
AU - Yuan, Xiaodong
AU - Song, Cai
AU - Meshalkina, Darya A.
AU - Leonard, Brian E.
AU - Tian, Li
AU - Kalueff, Allan V.
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/10/3
Y1 - 2017/10/3
N2 - Introduction: Depression, anxiety and other affective disorders are globally widespread and severely debilitating human brain diseases. Despite their high prevalence and mental health impact, affective pathogenesis is poorly understood, and often remains recurrent and resistant to treatment. The lack of efficient antidepressants and presently limited conceptual innovation necessitate novel approaches and new drug targets in the field of antidepressant therapy. Areas covered: Herein, the authors discuss the emerging role of neuro-immune interactions in affective pathogenesis, which can become useful targets for CNS drug discovery, including modulating neuroinflammatory pathways to alleviate affective pathogenesis. Expert opinion: Mounting evidence implicates microglia, polyunsaturated fatty acids (PUFAs), glucocorticoids and gut microbiota in both inflammation and depression. It is suggested that novel antidepressants can be developed based on targeting microglia-, PUFAs-, glucocorticoid- and gut microbiota-mediated cellular pathways. In addition, the authors call for a wider application of novel model organisms, such as zebrafish, in studying shared, evolutionarily conserved (and therefore, core) neuro-immune mechanisms of depression.
AB - Introduction: Depression, anxiety and other affective disorders are globally widespread and severely debilitating human brain diseases. Despite their high prevalence and mental health impact, affective pathogenesis is poorly understood, and often remains recurrent and resistant to treatment. The lack of efficient antidepressants and presently limited conceptual innovation necessitate novel approaches and new drug targets in the field of antidepressant therapy. Areas covered: Herein, the authors discuss the emerging role of neuro-immune interactions in affective pathogenesis, which can become useful targets for CNS drug discovery, including modulating neuroinflammatory pathways to alleviate affective pathogenesis. Expert opinion: Mounting evidence implicates microglia, polyunsaturated fatty acids (PUFAs), glucocorticoids and gut microbiota in both inflammation and depression. It is suggested that novel antidepressants can be developed based on targeting microglia-, PUFAs-, glucocorticoid- and gut microbiota-mediated cellular pathways. In addition, the authors call for a wider application of novel model organisms, such as zebrafish, in studying shared, evolutionarily conserved (and therefore, core) neuro-immune mechanisms of depression.
KW - affective disorders
KW - animal models
KW - Depression
KW - drug discovery
KW - neuroimmune modulation
KW - neuroinflammation
UR - http://www.scopus.com/inward/record.url?scp=85028764787&partnerID=8YFLogxK
U2 - 10.1080/17460441.2017.1362385
DO - 10.1080/17460441.2017.1362385
M3 - Review article
C2 - 28816544
AN - SCOPUS:85028764787
SN - 1746-0441
VL - 12
SP - 995
EP - 1009
JO - Expert Opinion on Drug Discovery
JF - Expert Opinion on Drug Discovery
IS - 10
ER -